Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs

PITTSBURGH, Apr. 29 /PRNewswire/ --

PITTSBURGH, April 29 /PRNewswire-FirstCall/ -- Mylan Inc. today announced the appointment of Michael J. Monroe as senior vice president - Global Public Affairs and as a member of the company's senior leadership team. In this role, Monroe is responsible globally for executive, financial and employee communications; corporate branding/marketing; corporate media relations; Internet management, sponsorships and event planning. In addition, he oversees the strategic coordination of communications for the company, working closely with Mylan's operating and support units.

"Mike is a talented and experienced senior executive," said Mylan's Vice Chairman and CEO Robert J. Coury. "His broad-based background and understanding of international public affairs will serve Mylan well as we strengthen our strategic global communications activities. We are fortunate to have added someone of Mike's caliber to Mylan's senior leadership team."

Monroe served previously as executive vice president - Public Affairs and chief communications officer for KeyCorp, one of the nation's largest financial services companies. During his 30 year career, he also completed assignments of increasing responsibility at CIGNA Corporation, The American Express Company and AT&T Long Lines Division.

Monroe earned a bachelor's degree from Rutgers University, graduating magna cum laude. He also holds a master's degree in journalism from Columbia University.

He is a member of The Phi Beta Kappa Society, The Public Relations Seminar and The Wisemen. He has chaired the Public Affairs Council of The Financial Services Roundtable and is the former chair of The Conference Board's Communications Council.

Mylan Inc., with operations in more than 90 countries, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's second largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.